Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
A Nantahala Capital Partners Schedule 13G filed for ABEONA THERAPEUTICS INC. reports shared beneficial ownership of 5.09% of common stock as of 09/29/2025. Nantahala discloses beneficial ownership of 2,618,462 shares, which includes 179,832 shares exercisable within sixty days. The filing states Nantahala holds no sole voting or dispositive power and reports shared voting and dispositive power for the full amount. The ownership percentage is calculated using a reported outstanding share count of 51,278,539 shares from the issuer's Form 10-Q for the period ended 06/30/2025. Signatures by compliance and management representatives are dated 10/06/2025.
ABEO Form 4 summary: Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (ABEO), reported a sale of 9,366 shares of common stock on 09/29/2025 at a weighted average price of $5.3935 per share. After the sale, he beneficially owns 350,763 shares. The filing states the sale was executed to cover tax obligations arising from the vesting of restricted stock awards and that the reported price reflects multiple transactions ranging from $5.35 to $5.46.
Insider sales reported by Vishwas Seshadri, CEO and Director of Abeona Therapeutics (ABEO). The Form 4 shows two non-derivative sales: 19,274 shares sold on 09/29/2025 at a weighted average price of $5.3935 to cover tax obligations from restricted stock vesting, and 25,000 shares sold on 09/30/2025 at a weighted average price of $5.2372 under an existing Rule 10b5-1 trading plan. The reporting persons beneficial ownership decreased from 1,215,067 shares to 1,190,067 shares following these transactions. The filing is signed by Vishwas Seshadri on 10/01/2025.
Joseph Walter Vazzano, Chief Financial Officer of ABEONA THERAPEUTICS INC. (ABEO), reported the sale of 9,035 shares of common stock on 09/29/2025. The disclosed weighted-average price was $5.3935 per share, with individual trade prices ranging between $5.35 and $5.46. The filing states the shares were sold to cover tax obligations arising from the vesting of restricted stock awards. After the reported sale, the reporting person beneficially owned 453,631 shares, held directly. The Form 4 reflects a routine tax-related disposition rather than a market-timing or strategic sale.
Form 144 notice for Abeona Therapeutics, Inc. (ABEO): The filer reports a proposed sale of 44,274 shares of common stock through Stifel Nicolaus & Company, to be executed on 09/29/2025 on Nasdaq with an aggregate market value of $238,792.00. The shares were acquired as 38,800 restricted stock units on 09/28/2025 and payment is noted as cash on 09/29/2025. The filing shows 51,156,736 shares outstanding for the issuer. The form also discloses a sale by Vishwas Seshadri of 69,420 shares on 07/09/2025 for $406,503.00. The notice contains the standard insider representation regarding material nonpublic information.
A Form 144 notice shows a proposed sale of 9,366 shares of common stock of Abeona Therapeutics, Inc. (ticker ABEO) by Brendan O'Malley. The shares are listed with an aggregate market value of $50,516.00 and the filer lists Nasdaq as the exchange. The filing states the shares were acquired as Restricted Stock Units on 09/29/2025 and payment is shown as cash. The table of recent sales also records a sale by Brendan O'Malley of 9,366 shares on 09/22/2025 for gross proceeds of $50,515.00. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Abeona Therapeutics (ABEO) Form 144: An insider notice shows a proposed sale of 9,366 shares of common stock to be executed on 09/29/2025 through Stifel Nicolaus. The filing states these shares were acquired as restricted stock units on 09/28/2025 and the aggregate market value of the proposed sale is listed as $50,516.00. The filing also discloses three recent sales by the same person, Joseph Vazzano, totaling 41,913 shares sold on 07/09/2025, 07/22/2025, and 09/29/2025 with gross proceeds of $148,799.00, $9,974.63, and $110,358.00 respectively. The filer certifies no undisclosed material adverse information.
Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics, reported a single non-derivative transaction on 09/22/2025. The Form 4 shows a sale of 688 shares of Abeona common stock at $5.43 per share, executed to cover tax obligations tied to the vesting of restricted stock awards. After the sale, Mr. O'Malley is reported to beneficially own 360,129 shares directly. The filing is submitted by one reporting person and is signed by Mr. O'Malley on 09/22/2025. The disclosure is limited to this transaction and its stated tax-related purpose.
Abeona Therapeutics (ABEO) Form 144 shows a proposed sale of 17,376 shares of common stock through Stifel Nicolaus & Company on 09/22/2025 with an aggregate market value of $101,749. The filing lists total shares outstanding of 51,156,736, so the proposed sale equals a small fraction of the outstanding float. The notice records an acquisition of 1,360 shares as Restricted Stock Units on 09/21/2025 with cash payment on 09/22/2025. It also discloses a sale by Brendan O'Malley of 17,428 shares on 07/09/2025 for gross proceeds of $102,053. The filer attests there is no undisclosed material adverse information.
Eric Crombez, a director of Abeona Therapeutics Inc. (ABEO), reported a sale of 4,718 shares of the company's common stock on 08/14/2025. The sale was executed to cover tax obligations arising from the vesting of restricted stock awards and was reported at a weighted average price of $6.9273, with individual trade prices ranging from $6.77 to $7.05. After the reported disposition, the reporting person beneficially owned 42,427 shares. The filing discloses the transaction code "S" indicating a sale and affirms that detailed per-trade price information can be provided on request.